Faisal Khurshid
Stock Analyst at Jefferies
(4.76)
# 281
Out of 5,182 analysts
43
Total ratings
65.62%
Success rate
51.62%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Assumes: Buy | $48 → $40 | $23.78 | +68.21% | 1 | Mar 30, 2026 | |
| FDMT 4D Molecular Therapeutics | Assumes: Buy | $40 → $21 | $10.07 | +108.54% | 1 | Mar 30, 2026 | |
| PTCT PTC Therapeutics | Downgrades: Hold | $91 → $76 | $72.32 | +5.09% | 1 | Mar 30, 2026 | |
| VSTM Verastem | Assumes: Buy | $19 → $15 | $6.52 | +130.06% | 1 | Mar 30, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $107 → $110 | $105.47 | +4.30% | 2 | Mar 19, 2026 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $122 → $110 | $86.93 | +26.54% | 4 | Mar 16, 2026 | |
| INSM Insmed | Assumes: Buy | $228 | $142.82 | +59.64% | 1 | Mar 16, 2026 | |
| COGT Cogent Biosciences | Assumes: Buy | $55 | $37.00 | +48.65% | 1 | Mar 16, 2026 | |
| DSGN Design Therapeutics | Initiates: Buy | $15 | $13.16 | +13.98% | 1 | Mar 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Buy | $160 | $114.98 | +39.15% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $420 → $290 | $318.07 | -8.83% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $522 → $330 | $310.94 | +6.13% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 → $94 | $96.92 | -3.01% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $16 | $15.40 | +3.90% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $4 | $3.91 | +2.30% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $29 → $40 | $29.28 | +36.61% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $13.47 | +48.48% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $0.85 | +17.21% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $2 | $7.88 | -74.62% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $102 | $87.72 | +16.28% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $1 | $4.42 | -77.38% | 2 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $73.39 | -38.68% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $17.04 | -6.10% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.29 | +55.04% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $81.73 | -2.12% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $5.37 | +179.33% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $18.36 | +145.10% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.56 | +348.72% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.92 | +173.97% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.96 | +423.56% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $2.62 | +319.85% | 1 | Mar 21, 2023 |
Syndax Pharmaceuticals
Mar 30, 2026
Assumes: Buy
Price Target: $48 → $40
Current: $23.78
Upside: +68.21%
4D Molecular Therapeutics
Mar 30, 2026
Assumes: Buy
Price Target: $40 → $21
Current: $10.07
Upside: +108.54%
PTC Therapeutics
Mar 30, 2026
Downgrades: Hold
Price Target: $91 → $76
Current: $72.32
Upside: +5.09%
Verastem
Mar 30, 2026
Assumes: Buy
Price Target: $19 → $15
Current: $6.52
Upside: +130.06%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $107 → $110
Current: $105.47
Upside: +4.30%
Kymera Therapeutics
Mar 16, 2026
Assumes: Buy
Price Target: $122 → $110
Current: $86.93
Upside: +26.54%
Insmed
Mar 16, 2026
Assumes: Buy
Price Target: $228
Current: $142.82
Upside: +59.64%
Cogent Biosciences
Mar 16, 2026
Assumes: Buy
Price Target: $55
Current: $37.00
Upside: +48.65%
Design Therapeutics
Mar 16, 2026
Initiates: Buy
Price Target: $15
Current: $13.16
Upside: +13.98%
ABIVAX Société Anonyme
Mar 16, 2026
Initiates: Buy
Price Target: $160
Current: $114.98
Upside: +39.15%
Mar 16, 2026
Downgrades: Hold
Price Target: $420 → $290
Current: $318.07
Upside: -8.83%
Mar 16, 2026
Downgrades: Hold
Price Target: $522 → $330
Current: $310.94
Upside: +6.13%
Mar 16, 2026
Downgrades: Hold
Price Target: $120 → $94
Current: $96.92
Upside: -3.01%
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $15.40
Upside: +3.90%
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.91
Upside: +2.30%
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $29.28
Upside: +36.61%
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $13.47
Upside: +48.48%
Sep 15, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.85
Upside: +17.21%
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $7.88
Upside: -74.62%
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $87.72
Upside: +16.28%
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $4.42
Upside: -77.38%
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $73.39
Upside: -38.68%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $17.04
Upside: -6.10%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.29
Upside: +55.04%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $81.73
Upside: -2.12%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $5.37
Upside: +179.33%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $18.36
Upside: +145.10%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.56
Upside: +348.72%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $2.92
Upside: +173.97%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.96
Upside: +423.56%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $2.62
Upside: +319.85%